Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
CSWYY'
s Equity-to-Asset Range Over the Past 10 Years
Min: 0.74 Med: 0.81 Max: 0.87
Current: 0.75
During the past 13 years, the highest Equity to Asset Ratio of China Shineway Pharmaceutical Group was 0.87. The lowest was 0.74. And the median was 0.81.
CSWYY's Equity-to-Asset is ranked better than 72.59% of 1007
companies
in the Drug Manufacturers industry
Industry Median: 0.61
vs CSWYY: 0.75
China Shineway Pharmaceutical Group (OTCPK:CSWYY) Equity-to-Asset Explanation
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
China Shineway Pharmaceutical Group Equity-to-Asset Related Terms
China Shineway Pharmaceutical Group Equity-to-Asset Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
China Shineway Pharmaceutical Group Equity-to-Asset Chart
For the Drug Manufacturers - Specialty & Generic subindustry, China Shineway Pharmaceutical Group's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
China Shineway Pharmaceutical Group Equity-to-Asset vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, China Shineway Pharmaceutical Group's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where China Shineway Pharmaceutical Group's Equity-to-Asset falls into.
China Shineway Pharmaceutical Group Equity-to-Asset Calculation
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
China Shineway Pharmaceutical Group (CSWYY) has a Equity-to-Asset of 0.75 as of Dec. 2025. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on China Shineway Pharmaceutical Group and its competitors. This is near median its historical median of 0.81. Over the past decade, China Shineway Pharmaceutical Group's Equity-to-Asset has ranged from 0.74 to 0.87. According to the industry distribution chart, China Shineway Pharmaceutical Group ranks #276 out of 1007 companies in the Drug Manufacturers industry, placing it in the top 27.4%.
Is China Shineway Pharmaceutical Group's Equity-to-Asset too high?
China Shineway Pharmaceutical Group's current Equity-to-Asset of 0.75 is near median its 10-year median of 0.81. Over the past 10 years, this metric has ranged from a low of 0.74 to a high of 0.87. The Drug Manufacturers industry median Equity-to-Asset is 0.61. China Shineway Pharmaceutical Group's value of 0.75 is 23% above this industry median. Based on the distribution chart, China Shineway Pharmaceutical Group ranks #276 out of 1007 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, China Shineway Pharmaceutical Group has a GF Scoreâ„¢ of 86/100, reflecting its overall financial health beyond just this single metric.
How does China Shineway Pharmaceutical Group's Equity-to-Asset compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, China Shineway Pharmaceutical Group ranks #276 out of 1007 companies for Equity-to-Asset. This puts China Shineway Pharmaceutical Group in the upper half of its industry. The industry median Equity-to-Asset is 0.61. China Shineway Pharmaceutical Group's value of 0.75 is 23% above this benchmark. Historically, China Shineway Pharmaceutical Group's own Equity-to-Asset has ranged from 0.74 to 0.87 over the past decade. While the company's 10-year median is 0.81 vs. the industry median of 0.61, China Shineway Pharmaceutical Group has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Drug Manufacturers company?
The median Equity-to-Asset among Drug Manufacturers companies is 0.61, based on 1,007 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. China Shineway Pharmaceutical Group's current Equity-to-Asset of 0.75 is 23% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on China Shineway Pharmaceutical Group and its competitors. For the Drug Manufacturers industry, the median Equity-to-Asset is 0.61 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. China Shineway Pharmaceutical Group's current Equity-to-Asset is 0.75, which is near median its own 10-year median of 0.81. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is China Shineway Pharmaceutical Group stock overvalued right now?
China Shineway Pharmaceutical Group (CSWYY) has a current Equity-to-Asset of 0.75. The stock's GF Value™ is $15.55, compared to a current price of $19.25 — trading 23.8% above its estimated fair value. The current Equity-to-Asset is 0.75, which is near median its 10-year median of 0.81 and 23% above the Drug Manufacturers industry median of 0.61. China Shineway Pharmaceutical Group's overall GF Score™ is 86/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For China Shineway Pharmaceutical Group (CSWYY), the current Equity-to-Asset is 0.75 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is China Shineway Pharmaceutical Group (CSWYY) Overvalued in 2026?
Based on GuruFocus' analysis, China Shineway Pharmaceutical Group stock appears to be overvalued.
The current stock price of $19.25 is trading 23.8% above its estimated GF Value™ of $15.55.
Key valuation signals for CSWYY:
Equity-to-Asset: 0.75 (near median its 10-year median of 0.81)
GF Value™: $15.55 vs. price of $19.25 (23.8% above fair value)
Industry Position: 23% above the Drug Manufacturers median (#276 of 1007)
No single metric tells the full story. See the CSWYY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
China Shineway Pharmaceutical Group Business Description
China Shineway Pharmaceutical Group Ltd is an investment holding company. Along with its subsidiaries, it is engaged in the research, development, manufacturing, and trading of modern Chinese medicines. The company's products comprise injection, soft capsule, granule, traditional Chinese medicine formula granules, and others, of which injections generate maximum revenue for the company. Geographically, the group operates in the People's Republic of China (PRC) and Hong Kong.
86GF Score
Get the complete analysis for CSWYY
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CSWYY has been successfully added to your 
